Details of the Drug

General Information of Drug (ID: DMPWB7T)

Drug Name
Maprotiline
Synonyms
Deprilept; Dibencycladine; Maprotilin; Maprotilina; Maprotilinum; Maprotylina; Maprotylina [Polish]; TBB066626; BA-34276; Deprilept (TN); Ludiomil (TN); Maprotilina [INN-Spanish]; Maprotiline (USAN); Maprotilinum [INN-Latin]; Psymion (TN); Ba-34,276; Maprotiline [USAN:BAN:INN]; N-Methyl-9,10-ethanoanthracene-9(10H)-propanamine; N-Methyl-9,10-ethanoanthracene-9(10H)-propylamine; 3-(9,10-Dihydro-9,10-ethanoanthracen-9-yl)propylmethylamine; 3-(9,10-ethanoanthracen-9(10H)-yl)-N-methylpropan-1-amine
Indication
Disease Entry ICD 11 Status REF
Major depressive disorder 6A70.3 Approved [1]
Therapeutic Class
Antidepressants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 277.4
Topological Polar Surface Area (xlogp) 4.6
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 1
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Bioavailability
68% of drug becomes completely available to its intended biological destination(s) [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 14 mL/min/kg [4]
Elimination
3% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 51 hours [4]
Metabolism
The drug is metabolized via the hepatic [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 11.5868 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.11% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 45 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 3.134 mg/mL [2]
Chemical Identifiers
Formula
C20H23N
IUPAC Name
N-methyl-3-(1-tetracyclo[6.6.2.02,7.09,14]hexadeca-2,4,6,9,11,13-hexaenyl)propan-1-amine
Canonical SMILES
CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24
InChI
InChI=1S/C20H23N/c1-21-14-6-12-20-13-11-15(16-7-2-4-9-18(16)20)17-8-3-5-10-19(17)20/h2-5,7-10,15,21H,6,11-14H2,1H3
InChIKey
QSLMDECMDJKHMQ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4011
ChEBI ID
CHEBI:6690
CAS Number
10262-69-8
DrugBank ID
DB00934
TTD ID
D03KQF
VARIDT ID
DR00515
INTEDE ID
DR1004
ACDINA ID
D00383

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Norepinephrine transporter (NET) TTAWNKZ SC6A2_HUMAN Inhibitor [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [8]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 06 Mental, behavioural or neurodevelopmental disorder
Disease Class ICD-11: 6A20 Schizophrenia
The Studied Tissue Pre-frontal cortex
The Studied Disease Major depressive disorder [ICD-11:6A20]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Norepinephrine transporter (NET) DTT SLC6A2 7.05E-01 7.02E-03 0.07
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 8.68E-01 3.64E-02 2.72E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 5.64E-01 2.36E-02 1.75E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Maprotiline
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Sertraline DM0FB1J Major Additive serotonergic effects by the combination of Maprotiline and Sertraline. Depression [6A70-6A7Z] [37]
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Maprotiline and Vilazodone. Depression [6A70-6A7Z] [37]
Nefazodone DM4ZS8M Major Additive serotonergic effects by the combination of Maprotiline and Nefazodone. Depression [6A70-6A7Z] [37]
Selegiline DM6034S Major Additive serotonergic effects by the combination of Maprotiline and Selegiline. Depression [6A70-6A7Z] [38]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Maprotiline and Vortioxetine. Depression [6A70-6A7Z] [37]
Isocarboxazid DMAF1NB Major Additive serotonergic effects by the combination of Maprotiline and Isocarboxazid. Depression [6A70-6A7Z] [38]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Maprotiline and Milnacipran. Depression [6A70-6A7Z] [37]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Maprotiline and Escitalopram. Depression [6A70-6A7Z] [39]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Maprotiline and Desvenlafaxine. Depression [6A70-6A7Z] [37]
Doxepin DMPI98T Moderate Additive anticholinergic effects by the combination of Maprotiline and Doxepin. Depression [6A70-6A7Z] [40]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Maprotiline and Esketamine. Depression [6A70-6A7Z] [41]
⏷ Show the Full List of 11 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Maprotiline (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Maprotiline and Methylene blue. Acquired methaemoglobinaemia [3A93] [38]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Maprotiline and Ivosidenib. Acute myeloid leukaemia [2A60] [42]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Midostaurin. Acute myeloid leukaemia [2A60] [39]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Idarubicin. Acute myeloid leukaemia [2A60] [39]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Gilteritinib. Acute myeloid leukaemia [2A60] [43]
Oliceridine DM6MDCF Moderate Additive serotonergic effects by the combination of Maprotiline and Oliceridine. Acute pain [MG31] [44]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Maprotiline and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [40]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Maprotiline and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [40]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Maprotiline and Memantine. Alzheimer disease [8A20] [45]
Rivastigmine DMG629M Moderate Antagonize the effect of Maprotiline when combined with Rivastigmine. Alzheimer disease [8A20] [46]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Maprotiline and Ivabradine. Angina pectoris [BA40] [47]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Maprotiline and Bepridil. Angina pectoris [BA40] [39]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Maprotiline and Dronedarone. Angina pectoris [BA40] [39]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Maprotiline and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [48]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Cilostazol. Arterial occlusive disease [BD40] [39]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Posaconazole. Aspergillosis [1F20] [39]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Maprotiline and Levalbuterol. Asthma [CA23] [49]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Pirbuterol. Asthma [CA23] [50]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Salbutamol. Asthma [CA23] [49]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Maprotiline and Formoterol. Asthma [CA23] [50]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [47]
Desipramine DMT2FDC Moderate Additive anticholinergic effects by the combination of Maprotiline and Desipramine. Attention deficit hyperactivity disorder [6A05] [45]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Ofloxacin. Bacterial infection [1A00-1C4Z] [51]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Clarithromycin. Bacterial infection [1A00-1C4Z] [39]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Maprotiline and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [39]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Gemifloxacin. Bacterial infection [1A00-1C4Z] [51]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Levofloxacin. Bacterial infection [1A00-1C4Z] [51]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Lomefloxacin. Bacterial infection [1A00-1C4Z] [39]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Telithromycin. Bacterial infection [1A00-1C4Z] [39]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Retigabine. Behcet disease [4A62] [39]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Maprotiline and Cariprazine. Bipolar disorder [6A60] [45]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Eribulin. Breast cancer [2C60-2C6Y] [39]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Lapatinib. Breast cancer [2C60-2C6Y] [39]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Maprotiline when combined with Acetylcholine. Cataract [9B10] [52]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Maprotiline and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [53]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Maprotiline and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [54]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Olodaterol. Chronic obstructive pulmonary disease [CA22] [50]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Maprotiline and Tiotropium. Chronic obstructive pulmonary disease [CA22] [54]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Maprotiline and Salmeterol. Chronic obstructive pulmonary disease [CA22] [50]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Maprotiline and Revefenacin. Chronic obstructive pulmonary disease [CA22] [54]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Maprotiline and Indacaterol. Chronic obstructive pulmonary disease [CA22] [50]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Maprotiline and Arformoterol. Chronic obstructive pulmonary disease [CA22] [50]
Dihydrocodeine DMB0FWL Moderate Additive serotonergic effects by the combination of Maprotiline and Dihydrocodeine. Chronic pain [MG30] [44]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Maprotiline and Levomilnacipran. Chronic pain [MG30] [37]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Maprotiline and Isoproterenol. Conduction disorder [BC63] [49]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Halothane. Corneal disease [9A76-9A78] [39]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Sevoflurane. Corneal disease [9A76-9A78] [39]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Probucol. Coronary atherosclerosis [BA80] [39]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Maprotiline and Pasireotide. Cushing syndrome [5A70] [39]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Osilodrostat. Cushing syndrome [5A70] [47]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Maprotiline and Mepenzolate. Digestive system disease [DE2Z] [45]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Maprotiline and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [55]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Maprotiline and Oxybutynine. Discovery agent [N.A.] [45]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [39]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Deutetrabenazine. Dystonic disorder [8A02] [56]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Ingrezza. Dystonic disorder [8A02] [57]
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Maprotiline and Solifenacin. Functional bladder disorder [GC50] [45]
Mirabegron DMS1GYT Moderate Decreased metabolism of Maprotiline caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [58]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Maprotiline and Tolterodine. Functional bladder disorder [GC50] [45]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Ketoconazole. Fungal infection [1F29-1F2F] [39]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Sunitinib. Gastrointestinal stromal tumour [2B5B] [39]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Maprotiline when combined with Pilocarpine. Glaucoma [9C61] [52]
Procarbazine DMIK367 Major Additive serotonergic effects by the combination of Maprotiline and Procarbazine. Hodgkin lymphoma [2B30] [38]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [59]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Maprotiline caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [60]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Maprotiline and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [61]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [39]
Givosiran DM5PFIJ Moderate Decreased metabolism of Maprotiline caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [62]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Maprotiline and Belladonna. Infectious gastroenteritis/colitis [1A40] [45]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Maprotiline caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [63]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Maprotiline and ITI-007. Insomnia [7A00-7A0Z] [45]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Maprotiline and Polyethylene glycol. Irritable bowel syndrome [DD91] [39]
Physostigmine DM2N0TO Moderate Antagonize the effect of Maprotiline when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [46]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Maprotiline caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [47]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Maprotiline and Crizotinib. Lung cancer [2C25] [64]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Maprotiline and Ceritinib. Lung cancer [2C25] [39]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Maprotiline caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [65]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Maprotiline and Osimertinib. Lung cancer [2C25] [66]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Maprotiline and Selpercatinib. Lung cancer [2C25] [47]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Maprotiline and Lumefantrine. Malaria [1F40-1F45] [41]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Maprotiline and Halofantrine. Malaria [1F40-1F45] [67]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Maprotiline and Hydroxychloroquine. Malaria [1F40-1F45] [68]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Primaquine. Malaria [1F40-1F45] [39]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [47]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Maprotiline and Arsenic trioxide. Mature B-cell lymphoma [2A85] [69]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Maprotiline and Vemurafenib. Melanoma [2C30] [39]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Maprotiline and LGX818. Melanoma [2C30] [70]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Maprotiline and Flibanserin. Mood disorder [6A60-6E23] [71]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Maprotiline and Thalidomide. Multiple myeloma [2A83] [72]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Maprotiline and Siponimod. Multiple sclerosis [8A40] [41]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Maprotiline and Fingolimod. Multiple sclerosis [8A40] [39]
Ozanimod DMT6AM2 Moderate Additive serotonergic effects by the combination of Maprotiline and Ozanimod. Multiple sclerosis [8A40] [73]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Romidepsin. Mycosis fungoides [2B01] [39]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Maprotiline caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [47]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Maprotiline and Nilotinib. Myeloproliferative neoplasm [2A20] [39]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Dasatinib. Myeloproliferative neoplasm [2A20] [74]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Maprotiline and Phenindamine. Nasopharyngitis [CA00] [45]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Maprotiline and Dimenhydrinate. Nausea/vomiting [MD90] [45]
Promethazine DM6I5GR Moderate Additive anticholinergic effects by the combination of Maprotiline and Promethazine. Nausea/vomiting [MD90] [45]
Rolapitant DM8XP26 Moderate Decreased metabolism of Maprotiline caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [75]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Maprotiline and Cyclizine. Nausea/vomiting [MD90] [45]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Maprotiline and Bupropion. Nicotine use disorder [6C4A] [39]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Entrectinib. Non-small cell lung cancer [2C25] [41]
Lorcaserin DMG6OYJ Moderate Decreased metabolism of Maprotiline caused by Lorcaserin mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [76]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Maprotiline and Dexfenfluramine. Obesity [5B80-5B81] [37]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Maprotiline and Levomethadyl Acetate. Opioid use disorder [6C43] [47]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Maprotiline and Apraclonidine. Optic nerve disorder [9C40] [77]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Rucaparib. Ovarian cancer [2C73] [39]
Oxymorphone DM65AGJ Moderate Additive serotonergic effects by the combination of Maprotiline and Oxymorphone. Pain [MG30-MG3Z] [44]
Dezocine DMJDB0Y Moderate Additive serotonergic effects by the combination of Maprotiline and Dezocine. Pain [MG30-MG3Z] [44]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Maprotiline and Flavoxate. Pain [MG30-MG3Z] [45]
Hydrocodone DMQ2JO5 Moderate Additive CNS depression effects by the combination of Maprotiline and Hydrocodone. Pain [MG30-MG3Z] [44]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Triclabendazole. Parasitic worm infestation [1F90] [39]
Safinamide DM0YWJC Major Additive serotonergic effects by the combination of Maprotiline and Safinamide. Parkinsonism [8A00] [73]
Rasagiline DM3WKQ4 Major Additive serotonergic effects by the combination of Maprotiline and Rasagiline. Parkinsonism [8A00] [38]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Pimavanserin. Parkinsonism [8A00] [78]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Maprotiline and Orphenadrine. Parkinsonism [8A00] [45]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Maprotiline and Methylscopolamine. Peptic ulcer [DA61] [45]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Maprotiline and Macimorelin. Pituitary gland disorder [5A60-5A61] [79]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Maprotiline and Lefamulin. Pneumonia [CA40] [80]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Degarelix. Prostate cancer [2C82] [47]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Maprotiline caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [81]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Enzalutamide. Prostate cancer [2C82] [47]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Bicalutamide. Prostate cancer [2C82] [47]
Levomepromazine DMIKFEL Moderate Additive anticholinergic effects by the combination of Maprotiline and Levomepromazine. Psychotic disorder [6A20-6A25] [45]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Maprotiline and Gatifloxacin. Respiratory infection [CA07-CA4Z] [82]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Quetiapine. Schizophrenia [6A20] [39]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Maprotiline and Iloperidone. Schizophrenia [6A20] [39]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Paliperidone. Schizophrenia [6A20] [39]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Maprotiline and Molindone. Schizophrenia [6A20] [45]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Maprotiline and Thiothixene. Schizophrenia [6A20] [45]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Maprotiline and Amisulpride. Schizophrenia [6A20] [83]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Asenapine. Schizophrenia [6A20] [39]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Maprotiline and Pimozide. Schizophrenia [6A20] [47]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Maprotiline and LEE011. Solid tumour/cancer [2A00-2F9Z] [39]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Maprotiline and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [39]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [47]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [39]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [39]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Lenvatinib. Thyroid cancer [2D10] [39]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Maprotiline and Cabozantinib. Thyroid cancer [2D10] [47]
Trimeprazine DMEMV9D Moderate Additive anticholinergic effects by the combination of Maprotiline and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [40]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Maprotiline and Acrivastine. Vasomotor/allergic rhinitis [CA08] [45]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Maprotiline and Procainamide. Ventricular tachyarrhythmia [BC71] [39]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Propafenone. Ventricular tachyarrhythmia [BC71] [39]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Maprotiline and Flecainide. Ventricular tachyarrhythmia [BC71] [39]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Maprotiline and Amiodarone. Ventricular tachyarrhythmia [BC71] [39]
⏷ Show the Full List of 147 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 1 E00263 19700 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Carmellose sodium E00625 Not Available Disintegrant
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Maprotiline 50 mg tablet 50 mg Oral Tablet Oral
Maprotiline 25 mg tablet 25 mg Oral Tablet Oral
Maprotiline 75 mg tablet 75 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 BDDCS applied to over 900 drugs
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Effect of pharmacologically selective antidepressants on serotonin uptake in rat platelets. Gen Physiol Biophys. 2005 Mar;24(1):113-28.
8 Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol Toxicol. 2002 Mar;90(3):144-9.
9 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
10 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
11 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
12 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
13 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
14 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
15 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
16 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
17 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
18 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
19 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
20 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
21 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
22 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
23 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
24 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
25 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
26 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
27 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
28 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
29 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
30 Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
31 Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
32 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
33 Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
34 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
35 Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
36 Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
37 Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
38 Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
39 Canadian Pharmacists Association.
40 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
41 Cerner Multum, Inc. "Australian Product Information.".
42 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
43 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
44 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
45 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
46 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
47 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
48 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
49 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
50 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
51 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
52 Multum Information Services, Inc. Expert Review Panel.
53 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
54 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
55 Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50. [PMID: 1968472]
56 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
57 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
58 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
59 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
60 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
61 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
62 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
63 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
64 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
65 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
66 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
67 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
68 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
69 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
70 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
71 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
72 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
73 Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
74 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
75 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
76 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
77 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
78 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
79 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
80 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
81 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
82 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
83 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.